ArticleAnnals of surgical oncology2026
Prognostic Impact of Hyperthermic Intraperitoneal Chemotherapy After Laparoscopic Gastrectomy in Gastric Cancer with Positive Peritoneal Lavage Cytology and no Other Noncurative Factors.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study was designed to evaluate the prognostic impact of laparoscopic gastrectomy combined with postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients exhibiting positive peritoneal lavage cytology (CY1) without visible metastases.
methodsData from 263 patients undergoing peritoneal lavage cytology and laparoscopic gastrectomy between December 2017 and December 2022 were retrospectively analyzed. Patients were stratified into CY1 (positive cytology) or CY0 (negative cytology) groups, with CY1 cases further subdivided into HIPEC and non-HIPEC cohorts based on postoperative HIPEC administration. Postoperative recurrence and survival outcomes were compared across cohorts.
resultsAmong 263 patients, 214 were CY0 and 49 CY1 with 27 CY1 patients receiving HIPEC and 22 non-HIPEC. HIPEC-treated CY1 patients demonstrated lower postoperative recurrence (66.7% vs. 90.9%) and visible peritoneal metastasis rates (29.6% vs. 59.1%) than non-HIPEC counterparts (P < 0.05). CY0 patients exhibited higher 3-year overall survival (OS) and progression-free survival (PFS) rates compared with both non-HIPEC CY1 and HIPEC-treated CY1 subgroups. HIPEC-treated CY1 patients showed superior 3-year OS (51.8% vs. 18.2%, P = 0.005) and PFS (35% vs. 13.6%, P = 0.037) than non-HIPEC CY1. Notably, stage III CY0 cohort demonstrated comparable survival outcomes to HIPEC-treated CY1 cohort (overall survival 56.4% vs. 51.8%, P = 0.39; progression-free survival 51% vs. 35%, P = 0.14). Cox analysis identified non-HIPEC and pN2-3 stage as independent risk factors for OS, while non-HIPEC, pT4, and pN2-3 stages predicted poorer PFS in CY1 patients.
conclusionsHyperthermic intraperitoneal chemotherapy following laparoscopic gastrectomy demonstrated efficacy in reducing postoperative peritoneal metastasis rates while enhancing prognosis of CY1 patients, achieving oncologic outcomes comparable to stage III CY0 counterparts, although additional investigation remains imperative.
Indexed as
Identifiers
41125986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.